Evotec Discloses Increased JPMorgan Stake After Major Holdings Notification

Evotec AG ( (EVO) ) has provided an update.

On January 6, 2026, Evotec SE reported that it had submitted notifications of major holdings to the German financial regulator, Bundesanstalt für Finanzdienstleistungsaufsicht, after JPMorgan Chase & Co. crossed a relevant ownership threshold in the company on December 30, 2025. The filing shows that JPMorgan’s total voting interest in Evotec rose to 5.51%, comprising 3.06% of voting rights attached to shares and 2.45% via financial instruments, signaling increased exposure by a major U.S. financial institution and providing investors with updated transparency on Evotec’s shareholder structure.

The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.

Spark’s Take on EVO Stock

According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.

Evotec AG’s overall stock score is primarily impacted by its weak financial performance and concerning valuation metrics. The company is struggling with profitability and cash flow issues, reflected in a negative P/E ratio and lack of dividend yield. Technical analysis shows a bearish trend, further weighing on the score. Despite some positive developments from the earnings call, such as growth in the Biologics segment and strategic partnerships, these are not enough to offset the significant financial challenges.

To see Spark’s full report on EVO stock, click here.

More about Evotec AG

Evotec SE is a Germany-based drug discovery and development company that provides integrated research and development services to the pharmaceutical and biotechnology industries, with a focus on early-stage discovery alliances and co-development partnerships with global healthcare players.

Average Trading Volume: 130,197

Technical Sentiment Signal: Sell

Current Market Cap: $1.15B

Learn more about EVO stock on TipRanks’ Stock Analysis page.